Bexotegrast

Product Description

PLN-74809, is a small-molecule, dual selective inhibitor of alphaVbeta1 / alphaVbeta6 for idiopathic pulmonary fibrosis (IPF) and primary sclerosing cholangitis (PSC). These integrins cause upstream activation of TGF-beta1 in actively fibrotic tissue. Inhibition of these integrins will block TGF-beta1 activation, thereby preventing the growth of fibrotic tissue within the lung and bile ducts. PLN-74809 has entered clinical testing, following FDA- approval of the IND. (Sourced from: https://www.pulmonaryfibrosis.org/patients-caregivers/medical-and-support-resources/clinical-trials-education-center/pipeline/drug/idiopathic-pulmonary-fibrosis/pln-74809)

Mechanisms of Action: aVb1 Inhibitor,aVb6 Inhibitor

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Oral

FDA Designation:
Fast Track - Cholangitis|Cholangitis, Sclerosing
Fast Track - Idiopathic Pulmonary Fibrosis|Pulmonary Fibrosis
Orphan Drug - Idiopathic Pulmonary Fibrosis|Pulmonary Fibrosis *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Pliant
Company Location: SOUTH SAN FRANCISCO CA 94080
Company CEO: Bernard Coulie
Additonal Commercial Interests: None